Home/Indications/Cardiovascular/Coronary Artery Disease

Coronary Artery Disease

Cardiovascular 3 original drugs

Novel Drugs

Reformulations

Drug Targets

Cardiovascular indication. Coronary Artery Disease has 3 FDA-approved novel treatments, led by BRACCO, with 167 active industry clinical trials across 11 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Coronary Artery Disease Market Leaders

Companies with the most FDA-approved novel Coronary Artery Disease drugs.

Phase 3 Readouts Pro

11 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

1-month DAPT

iVascular S.L.U.

Estimated · stale NCT05952206

Q4 2026

Inclisiran sodium 300 mg

Novartis

Estimated · fresh NCT05360446

Q4 2026

Vicagrel

Jiangsu vcare pharmaceutical technology co., LTD

Estimated · stale NCT06577519

Unlock 8 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Coronary Artery Disease Treatments by Mechanism

Top 10 mechanisms across 52 industry trials with a known mechanism of action.

See full pipeline →

Adenosine Receptor Agonist

7 trials 1 active 3 sponsors

P2Y12 Platelet Inhibitor

15 trials 4 sponsors

P2Y12

10 trials 3 sponsors

Factor Xa Inhibitor

4 trials 3 sponsors

Nonsteroidal Anti-inflammatory Drug

4 trials 1 sponsor

Anti-anginal

4 trials 1 sponsor

PCSK9 Inhibitor

3 trials 2 sponsors

Anti-coagulant

2 trials 2 sponsors

Contrast Agent for Ultrasound Imaging

2 trials 1 sponsor

Xanthine Oxidase Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Coronary Artery Disease Clinical Pipeline by Phase

271 industry-sponsored trials across 108 sponsors

View full landscape →

Showing 59 of 59 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
SPH Qingdao Growful Pharmacetical Co.,Ltd	Yangxinshi tablet	—	RECRUITING	2030-08-31	NCT07110415
CoreAalst BV	—	—	RECRUITING	2026-06-30	NCT05437900
Novartis	inclisiran sodium injection	—	ACTIVE NOT RECRUITING	2027-04-30	NCT06941792
Yuhan Corporation	Sarpogrelate Sustained Release/Aspirin	—	COMPLETED	2024-02-28	NCT05730621
Frisch Medical Device Private Limited	—	—	COMPLETED	2024-01-22	NCT07326735
Shanghai Hutchison Pharmaceuticals Limited	—	—	COMPLETED	2023-07-04	NCT04897126
Elixir Medical Corporation	—	—	COMPLETED	2022-12-31	NCT04483791
Biotronik AG	—	—	COMPLETED	2022-09-20	NCT04137510
Tanabe Pharma GmbH	Argatroban	Anti-coagulant [EPC]	COMPLETED	2021-05-06	NCT05740371
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company	Prasugrel	P2Y12	COMPLETED	2020-08-19	NCT03672097
Yuhan Corporation	high-dose rosuvastatin	—	COMPLETED	2019-07-23	NCT04056169
Boston Scientific Corporation	3 months of dual antiplatelet therapy (DAPT)	—	COMPLETED	2019-07-17	NCT02605447
Bristol-Myers Squibb	Apixaban	Factor Xa Inhibitor [EPC]	COMPLETED	2018-11-10	NCT02415400
Sanofi	Alirocumab SAR236553	—	COMPLETED	2018-07-27	NCT02984982
AstraZeneca	—	—	COMPLETED	2017-10-23	NCT02406677
Scitech Produtos Medicos SA	—	—	COMPLETED	2017-09	NCT02504307
Kobe University	EPA and high dose rosuvastatin	—	COMPLETED	2017-06-02	NCT03192579
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2015-09-30	NCT01870921
Sino Medical Sciences Technology Inc.	—	—	COMPLETED	2015-09	NCT02017275
Takeda	Febuxostat	Xanthine Oxidase Inhibitor [EPC]	COMPLETED	2015-03	NCT01763996
Abbott Medical Devices	clopidogrel + aspirin OR prasugrel + aspirin	—	COMPLETED	2015-02	NCT01106534
AstraZeneca	Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)	—	COMPLETED	2014-11	NCT02064985
Scitech Produtos Medicos SA	—	—	COMPLETED	2014-09	NCT01856088
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2014-08	NCT01589978
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2014-06	NCT01603082
Medtronic Vascular	Thienopyridine Therapy	—	COMPLETED	2014-04	NCT01069003
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2014-03	NCT01864005
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-09	NCT01523392
HK inno.N Corporation	Closone	—	COMPLETED	2013-08	NCT01765452
Les Laboratoires des Médicaments Stériles	ENOXA®	—	COMPLETED	2013-05	NCT01687491
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-05	NCT01523366
Medtronic Vascular	—	—	COMPLETED	2013-03	NCT00846846
Daiichi Sankyo	Prasugrel Loading Dose	—	COMPLETED	2013-02	NCT01587651
Abbott Medical Devices	—	—	COMPLETED	2012-10	NCT01178268
Gilead	Ranolazine	Anti-anginal [EPC]	COMPLETED	2012-10	NCT01425359
Guerbet	iobitridol	—	COMPLETED	2012-09	NCT01255722
Scitech Produtos Medicos SA	—	—	COMPLETED	2012-09	NCT01090609
Sahajanand Medical Technologies Limited	—	—	COMPLETED	2011-12	NCT01368627
Daiichi Sankyo	Prasugrel	P2Y12	COMPLETED	2011-09	NCT01260584
Infraredx	—	—	COMPLETED	2011-08	NCT00905671
Abbott Medical Devices	—	—	COMPLETED	2011-02	NCT01182428
Daiichi Sankyo	Prasugrel	P2Y12	COMPLETED	2010-05	NCT01014624
GSK	fondaparinux background and standard dose UFH	—	COMPLETED	2010-05	NCT00790907
Medtronic Vascular	—	—	COMPLETED	2010-05	NCT00617084
Sanofi	RAMIPRIL HOE498	—	COMPLETED	2010-04-23	NCT03099213
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Atorvastatin	—	COMPLETED	2010-04	NCT00728988
Astellas	Regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2009-12	NCT00863707
Astellas	Regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2009-10	NCT00862641
Forest Laboratories	Nebivolol	—	COMPLETED	2009-09	NCT00673075
Hanmi Pharmaceutical Company Limited	Clopidogrel	—	COMPLETED	2009-08	NCT01830491
Innogene Kalbiotech Pte. Ltd	Hypertonic sodium lactate	—	COMPLETED	2009-03	NCT01654653
Merck KGaA, Darmstadt, Germany	Nicorandil	—	TERMINATED	2019-07-09	NCT03010423
AstraZeneca	ticagrelor	P2Y12 Platelet Inhibitor [EPC]	TERMINATED	2015-04	NCT02052635
Sahajanand Medical Technologies Limited	—	—	TERMINATED	2011-03	NCT00936780
Sahajanand Medical Technologies Limited	—	—	TERMINATED	2010-05	NCT00917163
Gilead	Ranolazine	Anti-anginal [EPC]	TERMINATED	2009-06	NCT00832572
ECRI bv	Evolocumab	PCSK9 Inhibitor [EPC]	WITHDRAWN	2021-08-27	NCT03851263
ECRI bv	—	—	WITHDRAWN	2020-03-30	NCT03851276
Gilead	Ranolazine	Anti-anginal [EPC]	WITHDRAWN	2012-10	NCT01334203

Showing 83 of 83 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Jiangsu vcare pharmaceutical technology co., LTD	Vicagrel	—	RECRUITING	2026-12-30	NCT06577519
Novartis	Inclisiran	—	RECRUITING	2027-02-11	NCT07102628
Sinotau Pharmaceutical Group	XTR004	—	RECRUITING	2027-06	NCT07439133
DalCor Pharmaceuticals	Dalcetrapib	—	RECRUITING	2027-08	NCT05918861
ECRI bv	Ziltivekimab	—	RECRUITING	2028-09-01	NCT07276282
MedTrace Pharma A/S	[O-15]-Water PET Myocardial Perfusion Imaging (MPI)	—	RECRUITING	2026-04-30	NCT05134012
Novartis	Inclisiran sodium 300 mg	—	ACTIVE NOT RECRUITING	2026-10-26	NCT05360446
iVascular S.L.U.	1-month DAPT	—	ACTIVE NOT RECRUITING	2027-01-13	NCT05952206
NewAmsterdam Pharma	obicetrapib 10 mg + ezetimibe 10 mg FDC daily	—	ACTIVE NOT RECRUITING	2027-11	NCT06305559
EBI Anti Sepsis BV	EA-230 90mg/kg/hour	—	NOT YET RECRUITING	2027-03-24	NCT07357675
Novartis	Pelacarsen	—	NOT YET RECRUITING	2028-12-07	NCT07625306
Johnson & Johnson	Milvexian	—	COMPLETED	2026-02-06	NCT05754957
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	COMPLETED	2025-07-25	NCT03872401
Novartis	Inclisiran	—	COMPLETED	2024-08-07	NCT04873934
CSL Behring	Apolipoprotein A-I [human] (apoA-I)	—	COMPLETED	2023-02-16	NCT03473223
GE Healthcare	PET MPI	—	COMPLETED	2022-05-05	NCT03354273
DalCor Pharmaceuticals	dalcetrapib	—	COMPLETED	2021-10	NCT02525939
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	COMPLETED	2020-12-18	NCT03570697
Resverlogix Corp	Apabetalone	—	COMPLETED	2020-11-30	NCT02586155
Boston Scientific Corporation	—	—	COMPLETED	2020-01-16	NCT03350542
Scitech Produtos Medicos SA	—	—	COMPLETED	2019-07-30	NCT02400632
Dr. F. Köhler Chemie GmbH	Custodiol-N	—	COMPLETED	2018-11-16	NCT02098772
Johnson & Johnson	Rivaroxaban	Factor Xa Inhibitor [EPC]	COMPLETED	2018-04-19	NCT01877915
Bracco Diagnostics, Inc	Lumason	Contrast Agent for Ultrasound Imaging [EPC]	COMPLETED	2017-11-07	NCT02522481
Sujata Vaidya	SUVED	—	COMPLETED	2017-08	NCT02920125
Bracco Diagnostics, Inc	Lumason	Contrast Agent for Ultrasound Imaging [EPC]	COMPLETED	2017-06-22	NCT02552238
Sino Medical Sciences Technology Inc.	—	—	COMPLETED	2016-11	NCT02236975
Bayer	Gadobutrol (Gadavist, Gadovist, BAY86-4875)	—	COMPLETED	2016-08-06	NCT01890434
GSK	Losmapimod 7.5 mg twice daily	—	COMPLETED	2015-12-14	NCT02145468
ECRI bv	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2015-11-09	NCT01813435
Lisata Therapeutics, Inc.	Auto-CD34+ cells	—	COMPLETED	2015-11	NCT01508910
Medtronic Vascular	—	—	COMPLETED	2015-08	NCT02452736
Scitech Produtos Medicos SA	—	—	COMPLETED	2015-07	NCT01093391
Bayer	Gadobutrol (Gadovist, Gadavist, BAY86-4875)	—	COMPLETED	2015-04-10	NCT01890421
Sanofi	Lixisenatide (AVE0010)	—	COMPLETED	2015-02	NCT01147250
Gilead	Ranolazine	Anti-anginal [EPC]	COMPLETED	2015-02	NCT01442038
Astellas	Regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2014-12	NCT01618669
Boston Scientific Corporation	—	—	COMPLETED	2014-09	NCT01665053
Abbott Diagnostics Division	—	—	COMPLETED	2014-08	NCT01608100
Angel Medical Systems	—	—	COMPLETED	2014-05-01	NCT00781118
GSK	Darapladib 160 mg	—	COMPLETED	2014-04-01	NCT01000727
Air Liquide Santé International	Xenon	—	COMPLETED	2014-04	NCT01294163
Bayer	D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV	—	COMPLETED	2014-04	NCT00910065
Advanced Accelerator Applications	Rubidium-82	—	COMPLETED	2013-11	NCT01379677
The Medicines Company	Bivalirudin	Anti-coagulant [EPC]	COMPLETED	2013-08	NCT01087723
Lantheus Medical Imaging	Flurpiridaz F18	—	COMPLETED	2013-07	NCT01347710
Sanofi	Otamixaban	—	COMPLETED	2013-05	NCT01076764
Takeda	Alogliptin	—	COMPLETED	2013-04	NCT00968708
Novartis	Aliskiren	—	COMPLETED	2013-01	NCT00853827
Eli Lilly	Prasugrel	P2Y12	COMPLETED	2013-01	NCT01015287
The Medicines Company	cangrelor P2Y12 (platelet) inhibitor	—	COMPLETED	2012-12	NCT01156571
Boston Scientific Corporation	—	—	COMPLETED	2012-12	NCT01635881
Roche	Dalcetrapib (RO4607381)	—	COMPLETED	2012-09	NCT00658515
AbbVie (prior sponsor, Abbott)	ABT-335	—	COMPLETED	2012-09	NCT00616772
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2012-07	NCT01294462
Eli Lilly	Clopidogrel	—	COMPLETED	2012-04	NCT00699998
Roche	dalcetrapib	—	COMPLETED	2012-03	NCT01323153
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Rivaroxaban 2.5 mg	—	COMPLETED	2011-09	NCT00809965
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2011-03	NCT01500434
Boston Scientific Corporation	—	—	COMPLETED	2011-03	NCT01080261
Abbott Medical Devices	—	—	COMPLETED	2011-03	NCT00916370
Omicron Pharmaceuticals	—	—	COMPLETED	2011-03	NCT01272986
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2010-09	NCT00823212
Astellas	regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2010-07-15	NCT00826280
Eli Lilly	Prasugrel	P2Y12	COMPLETED	2010-06	NCT00830960
Kastle Therapeutics, LLC	Mipomersen sodium	—	COMPLETED	2010-05	NCT00770146
Kastle Therapeutics, LLC	Mipomersen	—	COMPLETED	2010-05	NCT00794664
Boston Scientific Corporation	Aspirin	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2010-02	NCT01510327
Ono Pharmaceutical Co., Ltd.	ONO-1101	—	COMPLETED	2010-02	NCT00924586
Kastle Therapeutics, LLC	mipomersen sodium	—	COMPLETED	2009-12	NCT00706849
Boston Scientific Corporation	—	—	COMPLETED	2009-09	NCT00824434
Merck	anacetrapib	—	COMPLETED	2009-07-02	NCT00685776
Cordis US Corp.	—	—	COMPLETED	2008-12	NCT00722579
Abbott	ABT-335	—	COMPLETED	2008-10	NCT00639158
Miltenyi Biotec B.V. & Co. KG	CD133+ autologous bone marrow stem cell	—	TERMINATED	2016-03	NCT00950274
Regado Biosciences, Inc.	pegnivacogin/anivamersen	—	TERMINATED	2014-08	NCT01848106
Forest Laboratories	Apadenoson SPECT-MPI	—	TERMINATED	2012-04	NCT01313572
Forest Laboratories	Apadenoson SPECT-MPI	—	TERMINATED	2012-04	NCT00990327
Anthera Pharmaceuticals	A-002, varespladib methyl	—	TERMINATED	2012-03	NCT01130246
Cordis US Corp.	—	—	TERMINATED	2011-11	NCT01202058
Bristol-Myers Squibb	Apixaban	Factor Xa Inhibitor [EPC]	TERMINATED	2011-03	NCT00831441
Lantheus Medical Imaging	Flurpiridaz F18	—	WITHDRAWN	2014-02	NCT01681524
AstraZeneca	90 mg Ticagrelor	—	WITHDRAWN	2013-04	NCT01757262

Showing 81 of 81 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Research Institute of Geroprotective Technologies	Aroxxen	—	RECRUITING	2026-10-01	NCT07397351
GE Healthcare	Regadenoson	Adenosine Receptor Agonist [EPC]	RECRUITING	2026-12	NCT04604782
XyloCor Therapeutics, Inc.	—	—	RECRUITING	2026-12-31	NCT07048808
Abcentra	Orticumab	—	RECRUITING	2027-02-08	NCT06927739
Sirius Therapeutics Co., Ltd.	SRSD107	—	RECRUITING	2027-12	NCT07318155
Beijing Inno Medicine Co., Ltd.	Dose 1 YN001	—	RECRUITING	2026-06	NCT06700720
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1002 Injection	—	RECRUITING	2024-12	NCT06533358
Elixir Medical Corporation	—	—	ACTIVE NOT RECRUITING	2022-12-02	NCT05033964
XyloCor Therapeutics, Inc.	XC001	—	NOT YET RECRUITING	2026-12-30	NCT07118449
Beijing Inno Medicine Co., Ltd.	YN001/Placebo 40mg	—	NOT YET RECRUITING	2027-07-31	NCT07521007
Hexun Biosciences Co., LTD.	HeXell-2020	—	NOT YET RECRUITING	2027-12-31	NCT07137104
Cell>Point LLC	—	—	NOT YET RECRUITING	2025-12	NCT01899833
Ribocure Pharmaceuticals AB	RBD4059	—	COMPLETED	2026-04-29	NCT06717074
Novartis	DFV890	—	COMPLETED	2024-12-17	NCT06031844
Novartis	MAS825	—	COMPLETED	2024-10-27	NCT06097663
AstraZeneca	MEDI6570	—	COMPLETED	2023-11-08	NCT04610892
Imbria Pharmaceuticals, Inc.	IMB-1018972	—	COMPLETED	2023-09-21	NCT04826172
Sinotau Pharmaceutical Group	XTR004	—	COMPLETED	2023-05-09	NCT05885841
XyloCor Therapeutics, Inc.	AdVEGFXC1	—	COMPLETED	2023-01-31	NCT04125732
Bristol-Myers Squibb	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2022-11-14	NCT05093790
Abcentra	Orticumab	—	COMPLETED	2022-11-11	NCT04776629
GE Healthcare	Flurpiridaz (18F) Injection	—	COMPLETED	2022-05-26	NCT04594941
AstraZeneca	AZD5718	—	COMPLETED	2020-04-08	NCT03317002
Jiangsu vcare pharmaceutical technology co., LTD	Vicagrel 5mg	—	COMPLETED	2019-06-11	NCT03599284
Medicure	Short Tirofiban	—	COMPLETED	2018-12	NCT01522417
MedImmune LLC	MEDI5884	—	COMPLETED	2018-11-09	NCT03351738
Viatris Innovation GmbH	Selatogrel	—	COMPLETED	2018-08-18	NCT03384966
Cerenis Therapeutics, SA	CER-001	—	COMPLETED	2016-11	NCT02484378
The Medicines Company	MDCO-216	—	COMPLETED	2016-10-26	NCT02678923
Johnson & Johnson	Acetylsalicylic acid	—	COMPLETED	2016-10-14	NCT02293395
MedImmune LLC	MEDI6012	—	COMPLETED	2016-08-20	NCT02601560
Novartis	Serelaxin	—	COMPLETED	2016-08-17	NCT01979614
Fluoropharma, Inc.	CardioPET™	—	COMPLETED	2016-07	NCT01826773
The Medicines Company	Cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2014-01-20	NCT01979445
The Medicines Company	Cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-07	NCT01852019
Roche	RO4905417	—	COMPLETED	2013-05	NCT01245634
Roche	MPSK3169A	—	COMPLETED	2013-05	NCT01609140
Resverlogix Corp	RVX000222	—	COMPLETED	2013-05	NCT01067820
The Medicines Company	cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2013-02	NCT01766466
Cell>Point LLC	—	—	COMPLETED	2013-02	NCT01778218
Bayer	UFH	—	COMPLETED	2013-01-29	NCT01442792
Cerenis Therapeutics, SA	CER-001	—	COMPLETED	2012-10	NCT01201837
Micell Technologies	—	—	COMPLETED	2012-09	NCT01247428
OrbusNeich	—	—	COMPLETED	2012-08	NCT01405287
Astellas	regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2012-07-02	NCT01334918
Micell Technologies	—	—	COMPLETED	2012-06	NCT01294748
Resverlogix Corp	RVX000222	—	COMPLETED	2012-06	NCT01423188
Dr. F. Köhler Chemie GmbH	Custodiol-N	—	COMPLETED	2012-05	NCT01444235
GSK	GW856553	—	COMPLETED	2012-03-06	NCT00910962
Corindus Inc.	—	—	COMPLETED	2011-12	NCT01275092
Eli Lilly	Prasugrel	P2Y12	COMPLETED	2011-11	NCT01115738
Terumo Europe N.V.	—	—	COMPLETED	2011-09	NCT01271361
The Medicines Company	cangrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2011-06	NCT00767507
AstraZeneca	ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2011-03	NCT01118325
Stereotaxis	—	—	COMPLETED	2011-03	NCT01131793
Ischemix, LLC	CMX-2043	—	COMPLETED	2011-03	NCT00984802
Astellas	YM150	—	COMPLETED	2011-02	NCT00994292
Regado Biosciences, Inc.	REG1	—	COMPLETED	2011-01	NCT00932100
Roche	Dalcetrapib (RO4607381)	—	COMPLETED	2010-11	NCT00655473
Molecular Targeting Technologies, Inc.	99mTc-glucarate solution	—	COMPLETED	2010-09	NCT00614354
Resverlogix Corp	RVX000222	—	COMPLETED	2010-06	NCT01058018
Takeda	TAK-442	—	COMPLETED	2010-06	NCT00677053
Roche	dalcetrapib	—	COMPLETED	2010-05	NCT00655538
Corindus Inc.	—	—	COMPLETED	2010-05	NCT01076036
Biotronik AG	—	—	COMPLETED	2010-04	NCT01214148
Anthera Pharmaceuticals	Varespladib Methyl (A-002)	—	COMPLETED	2010-01	NCT00743925
Resverlogix Corp	RVX000222	—	COMPLETED	2009-08	NCT00768274
AstraZeneca	Ticagrelor	P2Y12 Platelet Inhibitor [EPC]	COMPLETED	2009-03	NCT00642811
Eli Lilly	prasugrel	P2Y12	COMPLETED	2009-01	NCT00642174
Sinotau Pharmaceutical Group	XTR004	—	TERMINATED	2025-03-05	NCT07187895
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1002 for Injection	—	TERMINATED	2023-08-31	NCT04723186
Lisata Therapeutics, Inc.	CLBS16	—	TERMINATED	2022-09-28	NCT04614467
Sanofi	SAR407899	—	TERMINATED	2018-07-23	NCT03236311
Novartis	pradigastat (LCQ908)	—	TERMINATED	2014-06	NCT01474434
Resverlogix Corp	RVX000222	—	TERMINATED	2013-06	NCT01863225
PolyMedix, Inc.	PMX-60056	—	TERMINATED	2012-06	NCT01312935
Eli Lilly	Prasugrel	P2Y12	TERMINATED	2011-04	NCT00910299
Pfizer	Apixaban	Factor Xa Inhibitor [EPC]	TERMINATED	2010-12	NCT00852397
Gilead	regadenoson	Adenosine Receptor Agonist [EPC]	TERMINATED	2010-04	NCT00907764
TCA Cellular Therapy	MESENDO	—	SUSPENDED	2014-05	NCT00790764
Bayer	Riociguat (BAY63-2521)	—	WITHDRAWN	2013-01	NCT01165931

Showing 48 of 48 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Verve Therapeutics, Inc.	VERVE-102	—	RECRUITING	2026-08	NCT06164730
Shanghai CureGene Pharmaceutical Co., Ltd.	CG-0255 Besylate for Injection	—	RECRUITING	2026-10	NCT07619885
Roche	RO7763505	—	RECRUITING	2028-02-15	NCT07495813
Bayer	Nitroglycerin spray	—	NOT YET RECRUITING	2027-05-07	NCT07431294
Honya Medical Inc	MCRcI® stem cells	—	NOT YET RECRUITING	2026-01-01	NCT04052191
Jiangsu vcare pharmaceutical technology co., LTD	Vicagrel Capsules	—	COMPLETED	2025-08-22	NCT07067775
Indication Bioscience LLC	Atorvo+™ (Arm1)	—	COMPLETED	2025-05-14	NCT06615284
Brillian Pharma Inc.	Amlodipine Freeze-Dried Powder for Oral Solution 5 mg	—	COMPLETED	2023-04-17	NCT05808725
Jiangsu vcare pharmaceutical technology co., LTD	vicagrel Capsules	—	COMPLETED	2022-11-03	NCT05162053
Jiangsu vcare pharmaceutical technology co., LTD	vicagrel	—	COMPLETED	2021-10-20	NCT04919551
Sinotau Pharmaceutical Group	XTR003	—	COMPLETED	2021-08-27	NCT05136391
Sinotau Pharmaceutical Group	—	—	COMPLETED	2021-07-30	NCT05195879
AstraZeneca	AZD5718 tablet, Formulation A	—	COMPLETED	2020-03-09	NCT04210388
Shin Poong Pharmaceutical Co. Ltd.	SP-8008 Prototype Capsule A	—	COMPLETED	2020-01-23	NCT04770194
AstraZeneca	Treatment A	—	COMPLETED	2019-10-31	NCT04087187
Sanofi	SAR247799	—	COMPLETED	2018-12-22	NCT03462017
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2018-11-29	NCT03504982
AstraZeneca	AZD5718 oral suspension	—	COMPLETED	2018-06-12	NCT03400488
Chong Kun Dang Pharmaceutical	D578	—	COMPLETED	2018-06-04	NCT03671941
AstraZeneca	Form 1 of AZD5718 tablets	—	COMPLETED	2018-04-18	NCT03420092
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2018-02-07	NCT03255512
AstraZeneca	AZD5718 IR tablet	—	COMPLETED	2017-03-01	NCT02963116
Synektik S.A.	—	—	COMPLETED	2017-02	NCT02720354
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2016-05-18	NCT02617550
Bristol-Myers Squibb	BMS-919373	—	COMPLETED	2014-05	NCT02089061
GSK	Losmapimod	—	COMPLETED	2013-04-23	NCT01756495
LG Life Sciences	LC23-1306	—	COMPLETED	2012-11	NCT01526577
GSK	Losmapimod for single dose	—	COMPLETED	2012-10-26	NCT01648192
MedImmune LLC	ACP-501	—	COMPLETED	2012-09	NCT01554800
Yuhan Corporation	YH14659	—	COMPLETED	2012-04	NCT01657071
Fluoropharma, Inc.	BFPET	—	COMPLETED	2012-01	NCT00733460
Yuhan Corporation	YH14659	—	COMPLETED	2011-11	NCT01422109
Eli Lilly	prasugrel	P2Y12	COMPLETED	2011-10	NCT01107912
Chong Kun Dang Pharmaceutical	Clopidogrel and Aspirin	—	COMPLETED	2011-09	NCT01496261
Eli Lilly	prasugrel	P2Y12	COMPLETED	2011-08	NCT01107925
Lee's Pharmaceutical Limited	Anfibatide	—	COMPLETED	2011-03	NCT01588132
Chong Kun Dang Pharmaceutical	Clopidogrel	—	COMPLETED	2011-01	NCT01663038
Merck	Pantoprazole	—	COMPLETED	2010-12	NCT01358344
Novartis	APL180	—	COMPLETED	2009-10	NCT00907998
Lantheus Medical Imaging	[3H] BMS747158	—	COMPLETED	2009-07	NCT00930631
Merck	telcagepant	—	COMPLETED	2009-02-28	NCT01294709
TCA Cellular Therapy	MESENDO	—	COMPLETED	2008-12	NCT00643981
AstraZeneca	AZD6140	—	COMPLETED	2008-07	NCT00738842
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1002 for Injection	—	TERMINATED	2022-06-29	NCT05323136
IlDong Pharmaceutical Co Ltd	APD791	—	TERMINATED	2016-04	NCT02419820
IlDong Pharmaceutical Co Ltd	Clopidogrel	—	TERMINATED	2014-03	NCT02034292
Miltenyi Biotec, Inc.	—	—	TERMINATED	2013-10	NCT01721902
Eli Lilly	clopidogrel	—	TERMINATED	2010-12	NCT01107899

Novel Coronary Artery Disease Drugs by Company (New molecular entities)

3 companies have an FDA-approved novel drug for Coronary Artery Disease.

BRACCO 1 drug

CARDIOGEN-82

RUBIDIUM CHLORIDE RB-82

NDA 1989

GE HLTHCARE INC 1 drug

MEDI-PHYSICS 1 drug

TECHNETIUM TC-99M TETROFOSMIN KIT

NDA 1996

Reformulations (13 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.